Definition and epidemiology
Delayed puberty in a boy is conventionally defined as the absence of testicular enlargement (testicular volume <4 mL) by age 14 years, or failure to complete genital maturation within ~5 years of its onset. The reference threshold is statistical — roughly 2–2.5 SD beyond the population mean. The single commonest cause, by a wide margin, is constitutional delay of growth and puberty (CDGP) — a normal-variant “late bloomer” pattern, more often seen in boys, frequently familial, and benign in outcome. The clinical challenge is separating CDGP, which will progress spontaneously, from permanent hypogonadism — either hypogonadotropic (central, e.g. congenital GnRH deficiency/Kallmann, CNS lesions) or hypergonadotropic (primary testicular failure, e.g. Klinefelter syndrome, post-chemotherapy/orchitis).
Clinical features
The typical CDGP boy is short for age with a delayed growth tempo, a delayed bone age, prepubertal testicular volume, and often a parent or sibling who matured late. Contrast this with pointers to pathology: anosmia/hyposmia, midline defects, cryptorchidism or micropenis (suggesting congenital hypogonadotropic hypogonadism); eunuchoid proportions, small firm testes and gynaecomastia (Klinefelter); neurological symptoms, headache or visual field loss (CNS tumour); or systemic illness, undernutrition and chronic disease (functional/transient delay). A careful history of nutrition, chronic illness, medications, and a growth-chart review are central.
Diagnosis
First-line investigations are early-morning LH, FSH and testosterone plus a left-hand bone-age radiograph. Gonadotropins discriminate central from primary causes: low/normal LH and FSH cannot by themselves separate CDGP from hypogonadotropic hypogonadism, whereas elevated LH/FSH point to primary testicular failure and warrant a karyotype (Klinefelter). Bone age is delayed in CDGP and informs predicted adult height. Adjuncts include inhibin B and AMH (lower in hypogonadotropic hypogonadism than CDGP), prolactin, thyroid function, coeliac screen, and MRI brain/pituitary where a central lesion or anosmia is suspected. GnRH-stimulation testing is reserved for ambiguous cases.
See the full criteria: Delayed Puberty in Male
Red flags
- Anosmia, midline facial defects, cryptorchidism or micropenis — congenital hypogonadotropic hypogonadism
- Headache, visual disturbance, polyuria/polydipsia or other neurological signs — CNS/pituitary pathology
- Small firm testes with eunuchoid habitus and gynaecomastia — Klinefelter (karyotype)
- Elevated gonadotropins — primary gonadal failure
- Features of chronic systemic disease, malnutrition or eating disorder driving functional delay
Management overview
Most boys with CDGP need reassurance, explanation and active surveillance with serial height, testicular volume and bone-age review — puberty will progress on its own. Where the delay causes significant psychosocial distress, a short course of low-dose testosterone to prime puberty is a recognised paediatric-endocrinology option that does not compromise final height; this is a specialist decision and exact dosing is out of scope here. Confirmed hypogonadism requires endocrinology referral for hormone replacement and treatment of the underlying cause; suspected CNS lesions need urgent imaging and referral. In the Indian setting, exclude coeliac disease, thalassaemia/iron overload, chronic infection and undernutrition as contributors before labelling a delay constitutional.
References
- Merck Manual Professional Edition — Delayed Puberty.
- Pediatric Endocrine Society — Delayed Puberty (Boys).
- Palmert MR, Dunkel L. N Engl J Med. 2012;366:443–453; constitutional-delay management review, Italian J Pediatr. 2022.
Decision support for qualified clinicians only — verify against current primary guidelines and your clinical judgement.